KR100645385B1 - 비만 억제용 조성물 - Google Patents
비만 억제용 조성물 Download PDFInfo
- Publication number
- KR100645385B1 KR100645385B1 KR1020050093577A KR20050093577A KR100645385B1 KR 100645385 B1 KR100645385 B1 KR 100645385B1 KR 1020050093577 A KR1020050093577 A KR 1020050093577A KR 20050093577 A KR20050093577 A KR 20050093577A KR 100645385 B1 KR100645385 B1 KR 100645385B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- weight
- fat
- leaf extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000003579 anti-obesity Effects 0.000 title description 6
- 239000000284 extract Substances 0.000 claims abstract description 84
- 208000008589 Obesity Diseases 0.000 claims abstract description 56
- 235000020824 obesity Nutrition 0.000 claims abstract description 56
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 28
- 239000008280 blood Substances 0.000 claims abstract description 28
- 240000000249 Morus alba Species 0.000 claims abstract description 25
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 25
- 244000062730 Melissa officinalis Species 0.000 claims description 31
- 235000002789 Panax ginseng Nutrition 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 14
- 235000020688 green tea extract Nutrition 0.000 claims description 13
- 229940094952 green tea extract Drugs 0.000 claims description 13
- 235000013325 dietary fiber Nutrition 0.000 claims description 12
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 claims description 6
- 229940119569 wormwood extract Drugs 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 239000001904 Arabinogalactan Substances 0.000 claims description 2
- 229920000189 Arabinogalactan Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920002488 Hemicellulose Polymers 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 235000019312 arabinogalactan Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 229940025902 konjac mannan Drugs 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- 229920005610 lignin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 241000254043 Melolonthinae Species 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 52
- 230000000694 effects Effects 0.000 abstract description 35
- 235000012000 cholesterol Nutrition 0.000 abstract description 17
- 210000001789 adipocyte Anatomy 0.000 abstract description 15
- 241000092668 Artemisia capillaris Species 0.000 abstract description 4
- 235000008658 Artemisia capillaris Nutrition 0.000 abstract description 4
- 229940074968 melissa officinalis extract Drugs 0.000 abstract 5
- 239000003925 fat Substances 0.000 description 43
- 210000004003 subcutaneous fat Anatomy 0.000 description 29
- 230000004584 weight gain Effects 0.000 description 21
- 235000019786 weight gain Nutrition 0.000 description 21
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 20
- 240000006891 Artemisia vulgaris Species 0.000 description 20
- 210000000577 adipose tissue Anatomy 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 19
- 230000008859 change Effects 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 210000004907 gland Anatomy 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 210000001596 intra-abdominal fat Anatomy 0.000 description 12
- 235000009200 high fat diet Nutrition 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 238000013116 obese mouse model Methods 0.000 description 7
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 6
- 210000003934 vacuole Anatomy 0.000 description 6
- 101710095342 Apolipoprotein B Proteins 0.000 description 5
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- -1 etc.) Chemical compound 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229960004425 sibutramine Drugs 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 229940002552 xenical Drugs 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000005265 energy consumption Methods 0.000 description 3
- 230000002710 gonadal effect Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 229960003562 phentermine Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KUJLPCYCQICVRM-UHFFFAOYSA-N Capillarin Chemical compound C1=CC=C2C(=O)OC(CC#CC)=CC2=C1 KUJLPCYCQICVRM-UHFFFAOYSA-N 0.000 description 2
- WXQYRBLGGSLJHA-UHFFFAOYSA-N Capillene Chemical compound CC#CC#CCC1=CC=CC=C1 WXQYRBLGGSLJHA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920002752 Konjac Polymers 0.000 description 2
- 235000010654 Melissa officinalis Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 2
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 241000092666 Artemisia iwayomogi Species 0.000 description 1
- 235000007806 Artemisia iwayomogi Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHNBEBDYYSVNEK-XPQLPGEHSA-N Capillone Chemical compound C\C=C\C=C\C(=O)C1=CC=CC=C1 GHNBEBDYYSVNEK-XPQLPGEHSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- XXHSUYNZCSBPBG-GZIDCZEMSA-N quercetin 3-beta-gentiotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-GZIDCZEMSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- XXHSUYNZCSBPBG-UHFFFAOYSA-N quercetin-3-gentotrioside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC2C(C(O)C(O)C(OC=3C(C4=C(O)C=C(O)C=C4OC=3C=3C=C(O)C(O)=CC=3)=O)O2)O)O1 XXHSUYNZCSBPBG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- DOUMFZQKYFQNTF-ZZXKWVIFSA-N rosmarinic acid Chemical compound C=1C=C(O)C(O)=CC=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-ZZXKWVIFSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
시료 | 항목 | 대조군 | 처리군 | 감소율 |
비교예 시료 | 체중(g) | 47.0 ± 3.85 | 45.1 ± 4.22 | 4% |
체중증가(g) | 16.6 ± 2.24 | 14.4 ± 2.02 | 14% | |
피하지방(g) | 1.02 ± 0.15 | 0.95 ± 0.13 | 7% | |
성선지방(g) | 3.24 ± 0.23 | 3.13 ± 0.31 | 4% | |
시료 1 | 체중(g) | 47.0 ± 3.85 | 43.1 ± 4.17 | 8% |
체중증가(g) | 16.6 ± 2.24 | 12.1 ± 3.01 | 27% | |
피하지방(g) | 1.02 ± 0.15 | 0.87 ± 0.12 | 15% | |
성선지방(g) | 3.24 ± 0.23 | 3.01 ± 0.37 | 7% | |
시료 2 | 체중(g) | 47.0 ± 3.85 | 44.7 ± 4.20 | 5% |
체중증가(g) | 16.6 ± 2.24 | 12.5 ± 2.43 | 25% | |
피하지방(g) | 1.02 ± 0.15 | 0.93 ± 0.11 | 9% | |
성선지방(g) | 3.24 ± 0.23 | 3.11 ± 0.42 | 4% | |
시료 3 | 체중(g) | 47.0 ± 3.85 | 42.8 ± 4.31 | 9% |
체중증가(g) | 16.6 ± 2.24 | 11.3 ± 2.01 | 32% | |
피하지방(g) | 1.02 ± 0.15 | 0.82 ± 0.12 | 20% | |
성선지방(g) | 3.24 ± 0.23 | 2.92 ± 0.24 | 10% | |
시료 4 | 체중(g) | 47.0 ± 3.85 | 42.8 ± 4.44 | 9% |
체중증가(g) | 16.6 ± 2.24 | 11.8 ± 2.11 | 29% | |
피하지방(g) | 1.02 ± 0.15 | 0.83 ± 0.12 | 19% | |
성선지방(g) | 3.24 ± 0.23 | 2.95 ± 0.30 | 9% | |
시료 5 | 체중(g) | 47.0 ± 3.85 | 42.7 ± 4.01 | 9% |
체중증가(g) | 16.6 ± 2.24 | 12.5 ± 1.11 | 25% | |
피하지방(g) | 1.02 ± 0.15 | 0.85 ± 0.22 | 17% | |
성선지방(g) | 3.24 ± 0.23 | 2.98 ± 0.28 | 8% |
시료 | 항목 | 대조군 | 처리군 | 감소율 |
비교예 시료 | 체중(g) | 32.2 ± 2.40 | 31.2 ± 2.27 | 3% |
체중증가(g) | 11.1 ± 2.65 | 10.1 ± 2.58 | 10% | |
피하지방(g) | 0.82 ± 0.20 | 0.70 ± 0.19 | 15% | |
성선지방(g) | 0.41 ± 0.13 | 0.35 ± 0.12 | 16% | |
시료 1 | 체중(g) | 32.2 ± 2.40 | 30.4 ± 1.91 | 6% |
체중증가(g) | 11.1 ± 2.65 | 9.3 ± 2.89 | 16% | |
피하지방(g) | 0.82 ± 0.20 | 0.62 ± 0.12 | 24% | |
성선지방(g) | 0.41 ± 0.13 | 0.30 ± 0.06 | 27% | |
시료 2 | 체중(g) | 32.2 ± 2.40 | 30.6 ± 0.28 | 5% |
체중증가(g) | 11.1 ± 2.65 | 9.7 ± 1.90 | 12% | |
피하지방(g) | 0.82 ± 0.20 | 0.66 ± 0.20 | 19% | |
성선지방(g) | 0.41 ± 0.13 | 0.33 ± 0.11 | 20% | |
시료 3 | 체중(g) | 32.2 ± 2.40 | 29.9 ± 2.25 | 7% |
체중증가(g) | 11.1 ± 2.65 | 8.7 ± 1.98 | 21% | |
피하지방(g) | 0.82 ± 0.20 | 0.56 ± 0.21 | 32% | |
성선지방(g) | 0.41 ± 0.13 | 0.26 ± 0.08 | 37% | |
시료 4 | 체중(g) | 32.2 ± 2.40 | 29.7 ± 2.68 | 7% |
체중증가(g) | 11.1 ± 2.65 | 9.0 ± 1.57 | 19% | |
피하지방(g) | 0.82 ± 0.20 | 0.58 ± 0.19 | 29% | |
성선지방(g) | 0.41 ± 0.13 | 0.27 ± 0.11 | 34% | |
시료 5 | 체중(g) | 32.2 ± 2.40 | 30.2 ± 3.21 | 6% |
체중증가(g) | 11.1 ± 2.65 | 9.2 ± 2.43 | 17% | |
피하지방(g) | 0.82 ± 0.20 | 0.6 ± 0.12 | 27% | |
성선지방(g) | 0.41 ± 0.13 | 0.3 ± 0.11 | 27% |
대조군 | 처리군 | 감소율 | |
지방세포 (면적, a.u.) | 11.2 ± 2.9 | 6.1 ± 1.5 | 46% |
지방액포 (% area) | 5.4 ± 0.5 | 0.92 ± 0.1 | 83% |
피실험인(n=25) | ||
0주 | 12주 | |
남성 / 여성 | 3 / 22 | |
연령 (세) | 31.8±1.51 | |
신장 (cm) | 162.8±1.31 | |
체중 (kg) | 75.2±2.11 | 74.0±2.18* |
PIBW (%) | 133.3±3.17 | 131.2±3.40* |
BMI (kg/m2) | 28.4±0.67 | 27.9±0.72* |
체지방율 (%) | 39.4±1.46 | 37.2±1.38** |
제지방질량 (kg) | 45.3±1.40 | 46.2±1.40* |
허리둘레 (cm) | 91.4±1.73 | 90.0±1.78 |
엉덩이둘레 (cm) | 104.9±1.44 | 103.6±1.47** |
허리둘레/엉덩이둘레 비율 | 0.87±0.01 | 0.86±0.01 |
Tricep skinfold thickness (mm) | 26.1±1.32 | 26.2±0.91 |
수축기 혈압 (mmHg) | 125.3±3.38 | 124.2±2.64 |
이완기 혈압 (mmHg) | 77.5±2.09 | 82.2±2.46** |
흡연 여부 (n(%)) | 5(20) | |
일일 흡연량 | 7.70±3.03 | |
음주 여부 (n(%)) | 18 (72) | |
일일 알콜올 흡수량 (g/d) | 8.82±2.72 | |
평균 ± 표준오차. 0주의 수치와 비교한 *p<0.05, **p<0.01 |
피실험인(n=25) | ||
0주 | 12주 | |
1번 요추 (상복부) | ||
총지방 (cm2) | 260.9±13.1 | 256.6±12.2 |
내장지방 (cm2) | 99.4±6.54 | 98.7±5.59 |
피하지방 (cm2) | 161.5±9.66 | 157.9±9.43 |
내장지방/피하지방 비율 | 0.65±0.05 | 0.67±0.05 |
4번 요추 (하복부) | ||
총지방 (cm2) | 313.0±11.7 | 301.6±13.4 |
내장지방 (cm2) | 81.5±4.40 | 73.8±4.72** |
피하지방 (cm2) | 231.5±11.4 | 227.8±11.5 |
내장지방/피하지방 비율 | 0.38±0.03 | 0.33±0.02** |
허벅지 | ||
지방 (cm2) | 87.7±4.83 | 85.2±4.64 |
근육 (cm2) | 113.8±3.36 | 115.5±3.81 |
장딴지 | ||
지방 (cm2) | 29.8±1.84 | 30.1±2.00 |
근육 (cm2) | 73.4±2.84 | 72.9±3.31 |
평균 ± 표준오차. 0주의 수치와 비교한 **p<0.01 |
피실험인(n=25) | ||
0주 | 12주 | |
트리글리세라이드(mg/dl) | 124.9±11.0 | 119.2±10.7 |
총 콜레스테롤(mg/dl) | 203.3±6.97 | 197.1±6.36 |
LDL 콜레스테롤(mg/dl) | 126.7±6.29 | 119.7±5.99 |
HDL 콜레스테롤(mg/dl) | 51.6±2.21 | 53.6±2.38 |
동맥경화지수1 | 3.10±0.21 | 2.82±0.18* |
총 콜레스테롤/ HDL 콜레스테롤 | 4.10±0.21 | 3.82±0.18* |
LDL 콜레스테롤/ HDL 콜레스테롤 | 2.57±0.16 | 2.33±0.15* |
아포리포프로틴 A1(mg/dl) | 146.7±4.24 | 142.1±3.93 |
아포리포프로틴 B(mg/dl) | 81.6±3.80 | 75.4±3.23* |
혈당 (mg/dl) | 91.6±3.33 | 92.5±3.96 |
인슐린 (μIU/ml) | 12.4±1.10 | 11.7±1.30 |
유리지방산 (μEq/L) | 499.7±27.8 | 431.6±42.2 |
동맥경화지수1 = (총 콜레스테롤 - HDL 콜레스테롤) / HDL 콜레스테롤 평균 ± 표준오차. 0주의 수치와 비교한 *p<0.05 |
피실험인(n=25) | ||
0주 | 12주 | |
GOT (U/L) | 19.3±0.99 | 21.5±1.34 |
GPT (U/L) | 18.4±2.44 | 20.7±2.57 |
BUN (mg/dl) | 12.6±01.52 | 11.7±0.49 |
크레아틴 (mg/dl) | 0.52±0.03 | 0.52±0.03 |
백혈구 (×103/㎕) | 4.92±0.29 | 6.38±0.26*** |
적혈구 (×106/㎕) | 4.48±0.14 | 4.73±0.11* |
헤모글로빈 (g/dl) | 13.2±0.47 | 13.7±0.38 |
Hematocrit (%) | 38.7±1.38 | 40.0±1.11 |
혈소판 (×103/㎕) | 306.0±17.3 | 310.0±13.5 |
평균 ± 표준오차. 0주의 수치와 비교한 *p<0.05, ***p<0.001 |
피실험인(n=25) | ||
0주 | 12주 | |
TEE1 | 2029.8±36.6 | 2012.9±38.2 |
TCI2 | 2352.3±43.9 | 2325.0±45.4 |
TEE / TCI | 0.86±0.11 | 0.87±0.12 |
탄수화물 (% of TCI) | 62.5±0.43 | 62.1±0.26 |
단백질 (% of TCI) | 17.2±0.33 | 16.9±0.27 |
지방 (% of TCI) | 20.6±0.38 | 21.1±0.44 |
콜레스테롤 (mg) | 425.8±41.7 | 435.8±33.3 |
TEE1 = 총 에너지 소비량 TCI2 = 총 칼로리 섭취량 평균 ± 표준오차. 0주와 12주 사이에 특별한 변화가 없음 |
피실험인(n=25) | ||
0주 | 12주 | |
LDL 산화 | ||
산화 LDL (U/L) | 37.2±1.99 | 36.5±2.17 |
지질과산화물 | ||
MDA (nmol/mml) | 3.15±0.29 | 2.92±0.17 |
PGF2α(pg/mg creatinine) | 1391.2±145.8 | 1125.2±180.9 |
평균 ± 표준오차. 0주와 12주 사이에 특별한 변화가 없음 |
Claims (9)
- 멜리사엽 추출물을 유효성분으로 하는 비만 억제용 조성물.
- 제1항에 있어서, 상기 조성물 총 100 중량부에 대하여 멜리사엽 추출물은 0.1~95.0 중량부를 함유하는 것인 비만 억제용 조성물.
- 멜리사엽 추출물, 인진쑥 추출물 및 뽕나무잎 추출물을 유효성분으로 하는 비만 억제용 조성물.
- 제3항에 있어서, 상기 조성물 총 100 중량부에 대하여 멜리사엽 추출물은 0.1~95.0 중량부, 인진쑥 추출물은 0.1~60.0중량부, 뽕나무잎 추출물은 1.0~70.0중량부를 함유하는 것인 비만 억제용 조성물.
- 제3항에 있어서, 상기 멜리사엽추출물, 인진쑥 추출물, 뽕나무잎 추출물은 1~3: 0.1~1: 1~3의 건조중량비로 함유되는 것인 비만 억제용 조성물.
- 제1항 내지 제5항 중 어느 한 항의 조성물에 식이섬유, 녹차추출물, 홍삼추출물 중에서 선택된 1종 이상을 추가로 함유하는 비만억제용 조성물.
- 제6항에 있어서, 상기 식이섬유는 차전자피, 셀룰로오스, 헤미셀룰로오스, 결정셀룰로오스, 리그닌, 펙틴, 알긴산, 폴리만뉴로닉산, 구아검, 아라비아검, 아라비노갈락탄, 곤약만난, 이눌린, 레반, 폴리텍스트로스, 난소화성말토텍스트린 중에서 선택된 1종 이상인 것인 비만 억제용 조성물.
- 제6항에 있어서, 상기 녹차 추출물은 녹차 추출액 또는 녹차 추출액 분말인 비만 억제용 조성물.
- 제6항에 있어서, 상기 홍삼추출물은 홍삼 분말, 홍삼 추출액 또는 홍삼 추출액 분말인 비만 억제용 조성물.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050093577A KR100645385B1 (ko) | 2005-10-05 | 2005-10-05 | 비만 억제용 조성물 |
EP06799129.9A EP1951275B8 (en) | 2005-10-05 | 2006-10-09 | Antiobesity composition |
CA2624929A CA2624929C (en) | 2005-10-05 | 2006-10-09 | Antiobesity composition |
ES06799129.9T ES2581336T3 (es) | 2005-10-05 | 2006-10-09 | Composición antiobesidad |
CN200680036456.7A CN101277710B (zh) | 2005-10-05 | 2006-10-09 | 减肥组成物 |
AU2006297973A AU2006297973A1 (en) | 2005-10-05 | 2006-10-09 | Antiobesity composition |
JP2008534469A JP5284097B2 (ja) | 2005-10-05 | 2006-10-09 | 抗肥満組成物 |
PCT/KR2006/004049 WO2007040377A1 (en) | 2005-10-05 | 2006-10-09 | Antiobesity composition |
BRPI0617988-6A BRPI0617988A2 (pt) | 2005-10-05 | 2006-10-09 | composição anti-obesidade, uso de extrato de melissa, uso de uma mistura de extrato de melissa e extrato de mori folium, uso de uma mistura de extrato de melissa, extrato de artemisia e extrato de mori folium e método para suprimir a obesidade |
US12/059,611 US9155773B2 (en) | 2001-12-12 | 2008-03-31 | Antiobesity composition |
AU2011201268A AU2011201268B2 (en) | 2005-10-05 | 2011-03-22 | Antiobesity composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050093577A KR100645385B1 (ko) | 2005-10-05 | 2005-10-05 | 비만 억제용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100645385B1 true KR100645385B1 (ko) | 2006-11-23 |
Family
ID=37712520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050093577A KR100645385B1 (ko) | 2001-12-12 | 2005-10-05 | 비만 억제용 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9155773B2 (ko) |
EP (1) | EP1951275B8 (ko) |
JP (1) | JP5284097B2 (ko) |
KR (1) | KR100645385B1 (ko) |
CN (1) | CN101277710B (ko) |
AU (2) | AU2006297973A1 (ko) |
BR (1) | BRPI0617988A2 (ko) |
CA (1) | CA2624929C (ko) |
ES (1) | ES2581336T3 (ko) |
WO (1) | WO2007040377A1 (ko) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008123694A1 (en) * | 2007-04-04 | 2008-10-16 | Adipogen., Ltd. | Active extracts, containing scoparone, isolated from mugwort or chestnut peel having inhibitory effects on obesity |
KR100868261B1 (ko) | 2007-04-30 | 2008-11-11 | 한국식품연구원 | 근력 향상 활성을 갖는 조성물 |
WO2011065767A2 (ko) * | 2009-11-26 | 2011-06-03 | (주)아모레퍼시픽 | 퍼옥시좀 증식체 활성화 수용체 델타의 활성촉진 조성물 |
KR101108376B1 (ko) | 2009-04-08 | 2012-01-30 | 바이오스펙트럼 주식회사 | 아테미신 산을 함유하는 항비만, 항지방용 조성물 |
KR101539289B1 (ko) * | 2013-08-16 | 2015-07-24 | 한국국제대학교 산학협력단 | 개똥쑥 추출물을 함유하는 지방간 또는 비만의 예방 또는 치료용 조성물 |
KR20160118552A (ko) | 2015-04-02 | 2016-10-12 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
KR20170021270A (ko) | 2017-02-15 | 2017-02-27 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
KR20170076043A (ko) * | 2015-12-24 | 2017-07-04 | 오좌섭 | 광대나물 추출물을 이용한 항비만용 조성물 |
CN109511848A (zh) * | 2018-12-11 | 2019-03-26 | 北京康比特体育科技股份有限公司 | 一种具有减肥功能的代餐组合物 |
KR102036186B1 (ko) * | 2019-03-25 | 2019-10-24 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물 |
KR20200053344A (ko) | 2018-11-08 | 2020-05-18 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
KR102125244B1 (ko) * | 2018-12-14 | 2020-06-23 | 주식회사 휴앤코스메틱 | 지방 분해용 조성물 |
KR102143084B1 (ko) * | 2019-10-08 | 2020-08-11 | 주식회사 뉴트라코어 | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 |
WO2020197041A1 (ko) * | 2019-03-25 | 2020-10-01 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 주사제 및 화장료 조성물 |
KR20200135621A (ko) | 2019-05-23 | 2020-12-03 | 주식회사 하람 | 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 하는 비만 예방 및 치료소재 |
US10894071B2 (en) | 2007-08-23 | 2021-01-19 | Angiolab, Inc. | Fraction of melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same |
KR20210019051A (ko) | 2021-02-10 | 2021-02-19 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
KR20230098421A (ko) | 2021-12-24 | 2023-07-04 | 주식회사 앤드메이드 | 체중 감량용 조성물 및 그 제조방법 |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008050301A (ja) * | 2006-08-24 | 2008-03-06 | Prima Meat Packers Ltd | 膵リパーゼ阻害剤 |
EP2060192B9 (en) | 2007-10-17 | 2016-05-04 | Rudolf Wild GmbH & Co. KG | Composition comprising lemon balm extracts |
JP5503125B2 (ja) * | 2008-08-08 | 2014-05-28 | 静岡県公立大学法人 | 内臓脂肪蓄積抑制剤 |
CN101361774B (zh) * | 2008-09-01 | 2012-01-25 | 北京世纪博康医药科技有限公司 | 一种含有褐藻多糖硫酸酯和人参的组合物和其应用 |
US20130052284A1 (en) * | 2011-08-29 | 2013-02-28 | Carolyn J. Harrington | Palm kernel oil-based intranasal composition and use |
CN104736147B (zh) * | 2012-05-29 | 2018-05-18 | 尤妮金公司 | 用于控制体重的组合物和方法 |
JP2014097987A (ja) * | 2013-12-17 | 2014-05-29 | Shizuokaken Koritsu Daigaku Hojin | 内臓脂肪蓄積抑制剤 |
CN105899208A (zh) | 2014-01-10 | 2016-08-24 | 雀巢产品技术援助有限公司 | 对孕产妇施用维生素b6 预防后代发胖、超重或肥胖的增加 |
CN105899218A (zh) | 2014-01-10 | 2016-08-24 | 雀巢产品技术援助有限公司 | 对孕产妇施用维生素b12预防后代尤其是超重和/或肥胖母亲的后代发胖、超重或肥胖的增加 |
JP6338113B2 (ja) * | 2015-03-31 | 2018-06-06 | 株式会社東洋新薬 | 除脂肪体重の増加剤 |
KR101915071B1 (ko) | 2016-12-01 | 2018-11-20 | 주식회사 코시스바이오 | 커피 로부스타 발효 추출물을 유효성분으로 포함하는 비만 예방 및 개선용 식품 조성물 |
CN108902939A (zh) * | 2018-06-23 | 2018-11-30 | 袁维寨 | 一种用于减肥的组合物 |
JP2020164486A (ja) * | 2019-03-29 | 2020-10-08 | 丸善製薬株式会社 | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 |
CN113115881A (zh) * | 2019-12-31 | 2021-07-16 | 南京宿根花卉植物园有限公司 | 一种具有减肥功能的固体饮料 |
WO2021156184A1 (en) * | 2020-02-07 | 2021-08-12 | Dsm Ip Assets B.V. | New formulation of a plant extract |
BR112022019688A2 (pt) * | 2020-04-08 | 2022-11-22 | Angiolab Inc | Extrato de fração de folhas de melissa officinalis e nova composição farmacêutica incluindo o mesmo |
JP6923065B1 (ja) * | 2020-11-25 | 2021-08-18 | 大正製薬株式会社 | 経口固形組成物 |
CN113712206A (zh) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | 一种含有桑叶dnj和桑叶肽的组合物及其制备方法 |
CN113826799A (zh) * | 2021-09-26 | 2021-12-24 | 山东森健生物科技发展有限公司 | 减肥用食品 |
CN113875952A (zh) * | 2021-10-09 | 2022-01-04 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种减肥复合制剂及其制备方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2442633A1 (fr) | 1978-11-28 | 1980-06-27 | Kitasato Inst | Inducteurs d'interferon et leur procede de fabrication |
JPS6140763A (ja) * | 1984-08-02 | 1986-02-27 | Osaka Chem Lab | 抗肥満食品 |
FR2622110A1 (fr) | 1987-10-26 | 1989-04-28 | Marty Georges | Pile prevue pour l'utilisation du pouvoir radio-actif des plantes a des fins medicales |
JPH02256621A (ja) | 1988-12-28 | 1990-10-17 | King Jozo Kk | 抗変異原剤 |
CN1033945C (zh) * | 1992-12-09 | 1997-02-05 | 陈宗尧 | 一种保健花粉糖 |
JPH06199647A (ja) | 1992-12-28 | 1994-07-19 | Noevir Co Ltd | 美白化粧料 |
JPH07196526A (ja) | 1994-01-11 | 1995-08-01 | Takano Co Ltd | コラゲナーゼ阻害剤 |
JPH08301779A (ja) | 1995-05-01 | 1996-11-19 | Sansho Seiyaku Co Ltd | アトピー性皮膚炎用外用剤 |
JPH09241142A (ja) | 1996-03-06 | 1997-09-16 | Noevir Co Ltd | 皮膚外用剤 |
FR2751878B1 (fr) | 1996-07-30 | 1998-09-04 | Oreal | Utilisation dans une composition d'un extrait d'au moins une labiee |
KR19980021670U (ko) | 1996-10-22 | 1998-07-15 | 이영서 | 전자렌지 |
KR100257448B1 (ko) | 1997-08-01 | 2000-07-01 | 박홍락 | 항암, 기관분화유도, 암세포전이 혈관형성억제, 항산화 및 숙취해소 작용을 하는 옻나무 추출물, 이의 제조방법 및 이를 포함하는 조성물 |
DE69808790T3 (de) | 1997-09-12 | 2009-07-16 | The Procter & Gamble Co., Cincinnati | Hautreinigungs- und konditionierungsartikel für haut und haar |
JP3796340B2 (ja) | 1997-11-18 | 2006-07-12 | 株式会社ノエビア | セリンプロテアーゼ阻害剤 |
JPH11187843A (ja) * | 1997-12-25 | 1999-07-13 | Lotte Co Ltd | 肥満改善用の飲食組成物およびこれを含有する飲食物 |
JPH11335285A (ja) * | 1998-05-25 | 1999-12-07 | Toyotama Koryo Kk | 整腸・便秘改善剤およびこれを含有する飲食物並びに動物用飼料 |
FR2788438B1 (fr) * | 1999-01-14 | 2003-10-03 | Arkopharma Laboratoires | Composition pour le traitement de l'obesite et procede de traitement esthetique |
US20010024664A1 (en) | 1999-03-19 | 2001-09-27 | Obukowicz Mark G. | Selective COX-2 inhibition from edible plant extracts |
US6485756B1 (en) | 1999-04-06 | 2002-11-26 | Collaborative Technologies, Inc. | Stable, homogeneous natural product extracts containing polar and apolar fractions |
US6261566B1 (en) | 1999-10-22 | 2001-07-17 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Cosmetic compositions containing mulberry extract and retinoids |
KR100455222B1 (ko) * | 1999-12-31 | 2004-11-06 | 주식회사 한국인삼공사 | 다이어트 인삼복합제품 및 그 제조방법 |
US6416769B1 (en) | 2000-03-03 | 2002-07-09 | Australian Importers, Ltd. | Cosmetic compositions comprising exfoliating enzymes and uses thereof |
JP4173733B2 (ja) * | 2000-12-12 | 2008-10-29 | アンジオラボ・インコーポレイテッド | 抗−血管新生およびマトリックスメタロプロテイナーゼ阻害活性を有するメリッサ葉抽出物を含む組成物 |
DE10065832A1 (de) * | 2000-12-21 | 2002-06-27 | Bettina Kater | Mittel zur Gewichtsreduktion auf der Basis Minze, Melisse und Fenchel |
KR100451962B1 (ko) | 2001-07-18 | 2004-10-08 | 주식회사 대창중기계 | 지중 물막이 연속벽 구축 공법 및 장치 |
CA2459045A1 (en) * | 2001-08-31 | 2003-03-13 | Rutgers, The State University Of New Jersey | Antidiabetic extracts of artemisia dracunculus |
JP5127104B2 (ja) * | 2001-09-29 | 2013-01-23 | 小林製薬株式会社 | 便意を増進する香料組成物及び付香製品 |
KR100496622B1 (ko) * | 2002-04-29 | 2005-06-29 | (주) 김형민한약연구소 | 비만 억제를 위한 알콜 발효 식품 또는 약학적 조성물 및그의 제조방법 |
KR100828519B1 (ko) | 2002-07-12 | 2008-05-13 | 삼성전자주식회사 | 액정 패널과 이를 갖는 액정 표시 장치 |
EP1534082A4 (en) * | 2002-08-14 | 2006-05-10 | Bionutrigen Co Ltd | POWDER OR EXTRACTS FROM PLANT BLOOMS WITH EFFECTS OF GRAVITY AND COMPREHENSIVE GRAVITY OF ELASTIC FOOD |
JP2004217532A (ja) * | 2003-01-10 | 2004-08-05 | Maruzen Pharmaceut Co Ltd | 桑葉抽出物及びその製造方法、並びに血糖値上昇抑制用組成物及び肥満防止用組成物 |
KR100569792B1 (ko) | 2003-01-14 | 2006-04-10 | 학교법인 인제학원 | 인진쑥올리고당 aip1을 함유한 항비만성 바이오헬스 소재 |
KR20030026939A (ko) * | 2003-01-27 | 2003-04-03 | 최미회 | 구아바잎을 주성분으로한 당뇨병치료용, 비만개선용,노화방지용차의 효과적인 조성물 및 이를 함유한 건강식품 |
US6908573B2 (en) | 2003-04-17 | 2005-06-21 | General Electric | Polymeric resin blends and methods of manufacture thereof |
JP2005008572A (ja) * | 2003-06-19 | 2005-01-13 | Yakult Honsha Co Ltd | リパーゼ阻害剤 |
KR100549698B1 (ko) | 2003-07-12 | 2006-02-08 | 영 욱 김 | 활성탄 섬유를 이용한 발열구조 및 이를 적용한 전열기구 |
KR100521582B1 (ko) | 2003-07-15 | 2005-10-17 | 현대자동차주식회사 | 차량 시트의 사이드 팽창장치 |
KR100624488B1 (ko) * | 2004-02-03 | 2006-09-19 | 제일약품주식회사 | 비만의 예방 및 치료용 조성물 |
KR100716066B1 (ko) | 2004-02-21 | 2007-05-08 | 변상요 | 두충엽 추출물 및 상엽 추출물을 포함하는 비만억제 식품 |
JP4929611B2 (ja) * | 2004-04-09 | 2012-05-09 | 大正製薬株式会社 | リパーゼ阻害剤 |
KR20060070254A (ko) * | 2004-12-20 | 2006-06-23 | 김정훈 | 비만조절용 건강보조식품 및 그 제조방법 |
US20060280700A1 (en) * | 2005-06-08 | 2006-12-14 | Isler Stuart L | Oral hygiene system to fight the effects of aging on the mouth, gums, and teeth |
-
2005
- 2005-10-05 KR KR1020050093577A patent/KR100645385B1/ko active IP Right Grant
-
2006
- 2006-10-09 WO PCT/KR2006/004049 patent/WO2007040377A1/en active Application Filing
- 2006-10-09 ES ES06799129.9T patent/ES2581336T3/es active Active
- 2006-10-09 CN CN200680036456.7A patent/CN101277710B/zh not_active Expired - Fee Related
- 2006-10-09 CA CA2624929A patent/CA2624929C/en active Active
- 2006-10-09 EP EP06799129.9A patent/EP1951275B8/en active Active
- 2006-10-09 BR BRPI0617988-6A patent/BRPI0617988A2/pt not_active Application Discontinuation
- 2006-10-09 JP JP2008534469A patent/JP5284097B2/ja active Active
- 2006-10-09 AU AU2006297973A patent/AU2006297973A1/en not_active Abandoned
-
2008
- 2008-03-31 US US12/059,611 patent/US9155773B2/en not_active Expired - Fee Related
-
2011
- 2011-03-22 AU AU2011201268A patent/AU2011201268B2/en not_active Ceased
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008123694A1 (en) * | 2007-04-04 | 2008-10-16 | Adipogen., Ltd. | Active extracts, containing scoparone, isolated from mugwort or chestnut peel having inhibitory effects on obesity |
KR100868261B1 (ko) | 2007-04-30 | 2008-11-11 | 한국식품연구원 | 근력 향상 활성을 갖는 조성물 |
US10894071B2 (en) | 2007-08-23 | 2021-01-19 | Angiolab, Inc. | Fraction of melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same |
US11224629B2 (en) | 2007-08-23 | 2022-01-18 | Angiolab, Inc. | Fraction of Melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same |
KR101108376B1 (ko) | 2009-04-08 | 2012-01-30 | 바이오스펙트럼 주식회사 | 아테미신 산을 함유하는 항비만, 항지방용 조성물 |
US10183048B2 (en) | 2009-11-26 | 2019-01-22 | Amorepacific Corporation | Composition for promoting the activity of peroxisome proliferator-activated receptor-delta |
WO2011065767A3 (ko) * | 2009-11-26 | 2011-11-03 | (주)아모레퍼시픽 | 퍼옥시좀 증식체 활성화 수용체 델타의 활성촉진 조성물 |
WO2011065767A2 (ko) * | 2009-11-26 | 2011-06-03 | (주)아모레퍼시픽 | 퍼옥시좀 증식체 활성화 수용체 델타의 활성촉진 조성물 |
KR101539289B1 (ko) * | 2013-08-16 | 2015-07-24 | 한국국제대학교 산학협력단 | 개똥쑥 추출물을 함유하는 지방간 또는 비만의 예방 또는 치료용 조성물 |
KR20160118552A (ko) | 2015-04-02 | 2016-10-12 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
KR20170076043A (ko) * | 2015-12-24 | 2017-07-04 | 오좌섭 | 광대나물 추출물을 이용한 항비만용 조성물 |
KR101885949B1 (ko) * | 2015-12-24 | 2018-08-06 | 오좌섭 | 광대나물 추출물을 이용한 항비만용 조성물 |
KR20170021270A (ko) | 2017-02-15 | 2017-02-27 | 계명대학교 산학협력단 | 칡잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학조성물 |
KR20200053344A (ko) | 2018-11-08 | 2020-05-18 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
CN109511848A (zh) * | 2018-12-11 | 2019-03-26 | 北京康比特体育科技股份有限公司 | 一种具有减肥功能的代餐组合物 |
KR102125244B1 (ko) * | 2018-12-14 | 2020-06-23 | 주식회사 휴앤코스메틱 | 지방 분해용 조성물 |
KR102036186B1 (ko) * | 2019-03-25 | 2019-10-24 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물 |
JP2020158484A (ja) * | 2019-03-25 | 2020-10-01 | 林 載▲そん▼LIM, Jae Sun | レモンバーム抽出物を有効成分として含む注射剤及び化粧料組成物 |
WO2020197041A1 (ko) * | 2019-03-25 | 2020-10-01 | 임재선 | 레몬밤 추출물을 유효성분으로 포함하는 주사제 및 화장료 조성물 |
KR20200135621A (ko) | 2019-05-23 | 2020-12-03 | 주식회사 하람 | 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 하는 비만 예방 및 치료소재 |
WO2021070999A1 (ko) * | 2019-10-08 | 2021-04-15 | 주식회사 뉴트라코어 | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 |
KR102143084B1 (ko) * | 2019-10-08 | 2020-08-11 | 주식회사 뉴트라코어 | 비만, 당뇨, 고지혈증 및 지방간을 포함하는 대사증후군의 예방, 개선 또는 치료용 조성물 |
KR20210019051A (ko) | 2021-02-10 | 2021-02-19 | 충남대학교산학협력단 | 펙티넥스를 처리한 뽕나무 잎 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 약학 조성물 |
KR20230098421A (ko) | 2021-12-24 | 2023-07-04 | 주식회사 앤드메이드 | 체중 감량용 조성물 및 그 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
WO2007040377A1 (en) | 2007-04-12 |
ES2581336T3 (es) | 2016-09-05 |
US20080187606A1 (en) | 2008-08-07 |
CN101277710B (zh) | 2014-12-03 |
BRPI0617988A2 (pt) | 2011-08-16 |
JP5284097B2 (ja) | 2013-09-11 |
AU2006297973A1 (en) | 2007-04-12 |
AU2011201268B2 (en) | 2012-01-12 |
EP1951275B1 (en) | 2016-05-18 |
AU2011201268A1 (en) | 2011-04-14 |
US9155773B2 (en) | 2015-10-13 |
CA2624929C (en) | 2013-10-01 |
EP1951275B8 (en) | 2016-08-10 |
EP1951275A1 (en) | 2008-08-06 |
CA2624929A1 (en) | 2007-04-12 |
EP1951275A4 (en) | 2010-05-05 |
JP2009511468A (ja) | 2009-03-19 |
CN101277710A (zh) | 2008-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (ko) | 비만 억제용 조성물 | |
JP2009511468A5 (ko) | ||
US6541046B2 (en) | Herbal composition and method for controlling body weight and composition | |
CN110447902B (zh) | 一种具有减肥功效的组合物 | |
CN100998650A (zh) | 肉桂在治疗糖尿病上的用途及产品和其制备方法 | |
US11266668B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
KR100815200B1 (ko) | 항비만 효과를 갖는 홍삼 혼합 조성물 | |
KR20070113460A (ko) | 체중조절용 건강식품 조성물 | |
KR20100109697A (ko) | 체중감량 및 고지혈증 개선 효과가 있는 기능성 조성물 | |
KR100831621B1 (ko) | 혈당 강하용 식품 조성물 | |
CN101243883B (zh) | 一种具有降血糖功能的保健食品及其制备方法 | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
US10757961B2 (en) | Dietary supplement for glycemia control and diabetes prevention | |
EP1369123A1 (en) | A health-care product comprising lotus rhizome and process for its preparation | |
KR20090087671A (ko) | 두충을 이용한 고혈압 억제 음료 개발 | |
KR101511364B1 (ko) | 복합 생약재를 이용한 비만 및 대사증후군의 예방 또는치료용 조성물 | |
KR100815212B1 (ko) | 혈당과 체중 조절용 꾸지뽕잎 추출물과 난소화성말토덱스트린 배합물 | |
KR100293890B1 (ko) | 동아녹즙및그잔사를사용하여제조된체중및혈당조절용식품조성물및그제조방법 | |
KR100653460B1 (ko) | 뽕잎 추출물과 호로파 추출물을 함유한 항당뇨 조성물 | |
KR101695299B1 (ko) | 필발 추출물, 이소플라본을 함유하는 대두 추출물 및 l-카르니틴을 함유하는 비만 또는 고지혈증 예방용 또는 개선용 조성물 | |
KR101154182B1 (ko) | 방광과체질에 처방되는 변비개선용 천연음료 조성물 | |
KR100450055B1 (ko) | 두과 식물을 주성분으로 함유하는 체질개선용 식품 조성물및 그로부터 제조되는 식품 | |
KR100473529B1 (ko) | 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물 | |
RU2316972C1 (ru) | Кофе для похудения комплексного действия | |
KR20030059952A (ko) | 변방 소풍순기원 생약 복합제 추출물을 함유하는 당뇨병예방 및 치료를 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121106 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131023 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141104 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151103 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20161107 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171101 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181102 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191104 Year of fee payment: 14 |